Viking Therapeutics' obesity drug VKTX has shown promising Phase 2 data, competing with Eli Lilly in the market. Investors discuss VKTX's potential and CEO hints at a possible acquisition for all compounds.
$VKTX - new investors probably not aware of $VKTX obesity platform - as of yesterday I learned it’s even more then I thought - & exactly why clean takeout makes most sense especially for 8 big pharma with not much in the Obesity pipeline https://t.co/3LxafLWpEC
$VKTX one note from call that I specifically wrote down was CEO he mentioned “complete takeout” as that way he said you get ALL the compounds https://t.co/jmou0vXaRE
$VKTX correct JAY 60mg cohort finishing up and they meeting soon $VKTX mgt to see if they will be going higher https://t.co/oSeiEMUEkd
Obesity drugs keep getting linked to health benefits beyond weight loss, @yeahyeahyasmin writes—and it’s maddeningly difficult to figure out what’s causing them. https://t.co/qWFknYXB6X https://t.co/L8HAB9u9uq
$VKTX Let’s see what Jefferies puts out first-Brian excellent job - he is well aware of what he has and others things happening around him - excellent discussions.On oral -sub q. Platform - manufacturing -a lot of time on phase 2b vs phase 3 end game here👍 https://t.co/uOIqeo5uwh
Gilead Stock Gains. It’s Trying to Get Into the Obesity Drug Game. https://t.co/lCpxOehezo
$VKTX price games, fluctuations is not new. If you have invested in this company from under $5, you know stock has seen plenty of price fluctuations. I know this holding from under $5 but We know what we own, we know the data, data differentiation and safety all what matters…
$VKTX - great call BRIAN - he knows what he has https://t.co/UvEWrhZZdx
Bottom line his first preference is to sell the company, and they're talking. $vktx Jefferies
Facts 👇🏼 $VKTX https://t.co/hAiuBUIq8K
Either you give $LLY pretty much the whole obesity market for years, or you buy $VKTX and go head to head. Obviously they still need to invest in pipeline obesity drugs. It would be incredibly dumb of these other pharma's to let this asset go for what is the biggest TAM in the…
Dr. Steven Heymsfield of @PBRCNews speaks with @yeahyeahyasmin of @TheAtlantic about #ozempic health benefits ⬇️ https://t.co/RBpNBDGsWM
I'm excited by everyone else's excitement around #obesity #pharmacotherapy R&D https://t.co/mrpCKVaN3n @medscape I'm keeping my 👀 on: 👉 Amycretin: GLP1+amylin agonist 👉APHD-12: mysterious 🤔https://t.co/c4Tszc5RC4 👉VK2735: oral, subq GLP1+GIP agonist
Clearbridge on Viking Therapeutics $VKTX US the company has had positive Phase 2 data on a GLP-1/GIP agonist injectable candidate potentially differentiated in mechanism with encouraging results relative to existing approved/pipeline candidates (Extract from their Q1 letter) https://t.co/XjZBqU9XNq
Ozempic changed the lives of obesity patients. And then we had to stop prescribing it, via @IrishTimesOpEd https://t.co/gI5jmAjreU